Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to -$2.39.

  • Vanda Pharmaceuticals' EPS (Basic) fell 255555.56% to -$2.39 in Q4 2025 from the same period last year, while for Dec 2025 it was -$3.73, marking a year-over-year decrease of 103030.3%. This contributed to the annual value of -$3.74 for FY2025, which is 103333.33% down from last year.
  • Vanda Pharmaceuticals' EPS (Basic) amounted to -$2.39 in Q4 2025, which was down 255555.56% from -$0.38 recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' EPS (Basic) registered a high of $0.17 during Q2 2021, and its lowest value of -$2.39 during Q4 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' median EPS (Basic) value was -$0.02 (recorded in 2023), while the average stood at -$0.16.
  • Its EPS (Basic) has fluctuated over the past 5 years, first soared by 150000.0% in 2021, then crashed by 297595.15% in 2024.
  • Vanda Pharmaceuticals' EPS (Basic) (Quarter) stood at $0.13 in 2021, then decreased by 7.69% to $0.12 in 2022, then plummeted by 141.67% to -$0.05 in 2023, then plummeted by 80.0% to -$0.09 in 2024, then plummeted by 2555.56% to -$2.39 in 2025.
  • Its EPS (Basic) was -$2.39 in Q4 2025, compared to -$0.38 in Q3 2025 and -$0.46 in Q2 2025.